Literature DB >> 10952470

Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein?

R N Bergman1.   

Abstract

AIMS/HYPOTHESIS: Insulin control of glucose output is a major mechanism by which appropriate amounts of glucose are produced to supply energy to the central nervous system, without causing long-term increases of the plasma glucose concentration. It is hypothesised that the primary route by which insulin maintains control over glucose production is indirect and is mediated by regulation of non-esterified fatty acid release from the adipocyte. The question arises as to why evolution has chosen insulin to be secreted into the portal vein, if control of the liver is partially or primarily indirect. It is suggested that alterations in hepatic insulin clearance which attend increases in central adiposity are an important part of the compensation for insulin resistance and limit the necessity for up-regulation of insulin secretion in insulin resistance secondary to central adiposity.
METHODS: Review of research from author's group and other laboratories.
RESULTS: Data over the previous decade indicate that suppression of glucose output by increased insulin is a relatively slow process, much slower than the rate of binding of insulin to hepatocytes. One explanation is that insulin acts on an extrahepatic tissue, which in turn alters a signal to the liver, reducing glucose output. Additional evidence for an extrahepatic primary effect of insulin emerges from experiments in which insulin was given portally or peripherally at half the portal dose. Endogenous glucose production was related to systemic, not portal insulin, supporting the concept that the primary step in insulin's action on liver is on some other tissue, altering signalling to the liver itself. Strong correlation between plasma non-esterified fatty acids (NEFA) and liver glucose output suggests that the primary effect is on the adipocyte. The primacy of the adipocyte locus for the insulin effect included data that insulin's action on liver is prevented when plasma NEFA are maintained, as well as data showing proportional decline in glucose production and fatty acids when antilipolysis is induced by an adenosine agonist. Why then, from an evolutionary point of view is insulin secreted into the portal vein? Institution of central adiposity in dogs with fat feeding causes hepatic insulin resistance, at least partially due to the provision of NEFA in portal blood. The initial response to resistance is enhanced beta-cell sensitivity to glucose; a secondary compensation is, however, a substantial reduction in liver clearance, allowing for a greater proportion of secreted insulin to reach muscle, where it can more efficiently stimulate glucose utilisation. CONCLUSION/
INTERPRETATION: Non-esterified fatty acids act as a signal as well as a metabolic substrate. They can regulate glucose utilisation in muscle and apparently are important signals to the liver and the beta cells as well. The importance of portal vein NEFA concentrations to the function of the liver could explain insulin resistance of the liver with central pattern obesity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952470     DOI: 10.1007/s001250051474

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

Review 1.  Metabolic and molecular basis of insulin resistance.

Authors:  Mandeep Bajaj; Ralph A Defronzo
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

2.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

3.  Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.

Authors:  Tiffany D Farmer; Erin C Jenkins; Tracy P O'Brien; Gregory A McCoy; Allison E Havlik; Erik R Nass; Wendell E Nicholson; Richard L Printz; Masakazu Shiota
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-12-16       Impact factor: 4.310

Review 4.  Oral Insulin Delivery in a Physiologic Context: Review.

Authors:  Ehud Arbit; Miriam Kidron
Journal:  J Diabetes Sci Technol       Date:  2017-02-02

5.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

6.  Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.

Authors:  S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 7.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

8.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

Review 9.  Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination.

Authors:  Rudruidee Karnchanasorn; Horng-Yih Ou; James Lin; Lee-Ming Chuang; Ken C Chiu
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 10.  Control of glycaemia: from molecules to men. Minkowski Lecture 2003.

Authors:  M Stumvoll
Journal:  Diabetologia       Date:  2004-04-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.